// App-Quantinova.ai

AEP1025 : Medications used by individuals with fibrodysplasia ossificans progressiva (FOP): Data from a global natural history study

Researchers

Presenter

  • Edward C. Hsiao

Principal Investigators

  • Mona Al Mukaddam

  • Genevive Baujat

  • Carmen De Cunto

  • Richard Keen

  • Robert J Pignolo

  • Kathleen Harnett

  • Rose Marino

  • Frederick S Kaplan

Medical Centers

  • Division of Endocrinology and Metabolism, UCSF Metabolic Bone Clinic, Institute of Human Genetics, and UCSF Program in Craniofacial Biology, Department of Medicine, University of California-San Francisco, San Francisco, CA, United States

  • Departments of Orthopaedic Surgery and Genetics, Center for Research in FOP and Related Disorders, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA

  • Département de Génétique, Institut IMAGINE and Hôpital Universitaire Necker-Enfants Malades, Paris, France

  • Pediatric Rheumatology Section, Department of Pediatrics, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

  • Centre for Metabolic Bone Disease, Royal National Orthopaedic Hospital, Stanmore, United Kingdom

  • Department of Biomedical Statistics, Mayo Clinic, Rochester, Minnesota, United States

  • Ipsen, Boston, MA, United States

Locations

  • United States

  • France

  • Argentina

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • Fibrodysplasia ossificans progressiva

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved